Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long‐term outcome

• Published in: Alimentary pharmacology & therapeutics 2004-05, Vol.19 (9), p.999-1007
• Main Authors: Huo, T.‐I., Wu, J.‐C., Huang, Y.‐H., Chiang, J.‐H., Lee, P.‐C., Chang, F.‐Y., Lee, S.‐D.
• Format: Article
• Language: English
• Subjects: Acute Kidney Injury - etiology; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Carcinoma, Hepatocellular - therapy; Chemoembolization, Therapeutic - methods; Digestive system; Female; Follow-Up Studies; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Infusions, Intra-Arterial; Liver Neoplasms - therapy; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2004.01936.x

Summary Background : Transarterial chemoembolization is effective for hepatocellular carcinoma. Acute renal failure may occur after transarterial chemoembolization because of radiocontrast agent, but its clinical aspects are unknown. Aim : To investigate the incidence, risk factors and outcome of acute renal failure, defined as increase of serum creatinine > 1.5 mg/dL, after transarterial chemoembolization. Methods : A total of 235 hepatocellular carcinoma patients with 843 transarterial chemoembolization treatment sessions were analysed. Results : Acute renal failure developed in 56 (23.8%) patients and the estimated risk of developing acute renal failure was 6.6% in each treatment session. Comparison between the episodes of transarterial chemoembolization with and without acute renal failure by using the generalized estimating equation disclosed that Child–Pugh class B (odds ratio: 2.6, P = 0.007) and treatment session (odds ratio: 1.3; P